Assignee
ARDELYX INC
US·39 granted patents·24 pending applications·72 citations·filing 2013–2025
Top patents by PatentIndex Score
63 records- 0191US10793568B2Hormone receptor modulators for treating metabolic conditions and disordersARDELYX INC·Filed 2017·Granted Oct 6, 2020·4 cites·1 claims
- 0289US9408840B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorderARDELYX INC·Filed 2015·Granted Aug 9, 2016·6 cites·6 claims
- 0388US10543207B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2017·Granted Jan 28, 2020·3 cites·43 claims
- 0487US11242337B2Compounds useful for treating gastrointestinal tract disordersARDELYX INC·Filed 2018·Granted Feb 8, 2022·3 cites·20 claims
- 0587US10376481B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2017·Granted Aug 13, 2019·3 cites·32 claims
- 0687US8969377B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2013·Granted Mar 3, 2015·3 cites·7 claims
- 0786US10968246B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2019·Granted Apr 6, 2021·2 cites·27 claims
- 0886US9433640B2Compositions and methods for treating hyperkalemiaARDELYX INC·Filed 2016·Granted Sep 6, 2016·2 cites·29 claims
- 0986US8916569B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Dec 23, 2014·7 cites·44 claims
- 1086US8809339B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 19, 2014·8 cites·36 claims
- 1185US10272079B2NHE3-binding compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Apr 30, 2019·5 cites·15 claims
- 1285US8815910B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·38 claims
- 1385US8815908B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2013·Granted Aug 26, 2014·7 cites·32 claims
- 1485US2025115608A1Hormone receptor modulators for treating metabolic conditions and disordersARDELYX INC·Filed 2024·Application pending·0 cites
- 1584US11318129B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2020·Granted May 3, 2022·1 cites·19 claims
- 1683US12281103B2Compounds useful for treating gastrointestinal tract disordersARDELYX INC·Filed 2023·Granted Apr 22, 2025·0 cites·17 claims
- 1783US10385024B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2018·Granted Aug 20, 2019·3 cites·36 claims
- 1882US2024366589A1Nhe3-binding compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2024·Application pending·0 cites
- 1981US12016856B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2022·Granted Jun 25, 2024·0 cites·2 claims
- 2081US9006281B2Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2013·Granted Apr 14, 2015·1 cites·15 claims
- 2180US11091482B2Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activatorsARDELYX INC·Filed 2017·Granted Aug 17, 2021·3 cites·1 claims
- 2280US10392413B2Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonistsARDELYX INC·Filed 2016·Granted Aug 27, 2019·3 cites·39 claims
- 2379US2025067907A1Compounds and methods for treating hyperkalemiaARDELYX INC·Filed 2024·Application pending·0 cites
- 2478US10940146B2NHE3-binding compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2019·Granted Mar 9, 2021·1 cites·4 claims
- 2577US12209088B2Hormone receptor modulators for treating metabolic conditions and disordersARDELYX INC·Filed 2022·Granted Jan 28, 2025·0 cites·20 claims
- 2675US2023273354A1Glycyrrhetinic acid derivatives for treating hyperkalemiaARDELYX INC·Filed 2023·Application pending·0 cites
- 2775US2025263401A1Compounds useful for treating gastrointestinal tract disordersARDELYX INC·Filed 2025·Application pending·0 cites
- 2873US2022306610A1Compounds useful for treating gastrointestinal tract disordersARDELYX INC·Filed 2021·Application pending·0 cites
- 2972US2024209019A1Compounds and methods for treating hyperkalemiaARDELYX INC·Filed 2023·Application pending·0 cites
- 3070US2021186953A1Nhe3-binding compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2020·Application pending·0 cites
- 3169US11813304B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2019·Granted Nov 14, 2023·0 cites·14 claims
- 3269US2024366590A1Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2024·Application pending·0 cites
- 3369US2023277523A1Methods for inhibiting phosphate transportARDELYX INC·Filed 2022·Application pending·0 cites
- 3469US2025388615A9Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonistsARDELYX INC·Filed 2024·Application pending·0 cites
- 3568US2021017177A1Hormone receptor modulators for treating metabolic conditions and disordersARDELYX INC·Filed 2020·Application pending·0 cites
- 3667US9867848B2Compositions and methods for treating hyperkalemiaARDELYX INC·Filed 2017·Granted Jan 16, 2018·0 cites·26 claims
- 3767US2023313146A1Intestinal epithelial cell culturesARDELYX INC·Filed 2023·Application pending·0 cites
- 3866US2024325487A1Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2023·Application pending·0 cites
- 3965US9919006B2Compositions and methods for treating hyperkalemiaARDELYX INC·Filed 2016·Granted Mar 20, 2018·0 cites·28 claims
- 4064US9549947B2Pharmaceutical compositions for treating hyperkalemiaARDELYX INC·Filed 2016·Granted Jan 24, 2017·0 cites·28 claims
- 4164US9545425B2Pharmaceutical compositions for treating hyperkalemiaARDELYX INC·Filed 2016·Granted Jan 17, 2017·0 cites·28 claims
- 4263US11718619B2Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activatorsARDELYX INC·Filed 2021·Granted Aug 8, 2023·0 cites·4 claims
- 4363US2019374533A1Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2018·Application pending·0 cites
- 4462US9301951B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Apr 5, 2016·0 cites·40 claims
- 4559US11858959B2Glycyrrhetinic acid derivatives for use in treating hyperkalemiaARDELYX INC·Filed 2020·Granted Jan 2, 2024·0 cites·22 claims
- 4659US11768319B2Glycyrrhetinic acid derivatives for treating hyperkalemiaARDELYX INC·Filed 2018·Granted Sep 26, 2023·0 cites·18 claims
- 4758US9289429B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 22, 2016·0 cites·33 claims
- 4858US9289430B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 22, 2016·0 cites·35 claims
- 4958US9278102B2Compounds and methods for inhibiting phosphate transportARDELYX INC·Filed 2014·Granted Mar 8, 2016·0 cites·29 claims
- 5058US2025367188A1Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersARDELYX INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →